Saudi Arabia’s Vision 2030 serves as a transformative framework to diversify the economy and reduce dependency on oil, with healthcare identified as a critical sector for development.
Under this vision, significant investments are being made to modernize the healthcare system, improve access to medical services, and localize pharmaceutical production. Key initiatives, such as the National Transformation Program (NTP), aim to enhance healthcare infrastructure, promote public-private partnerships, and foster innovation in the pharmaceutical industry.
Fiscal Deficit (MOF)
+0
GDP increasing by 2.8%
Saudi Arabia’s economy grew moderately in 2024, with GDP increasing by 2.8% after stagnation in 2023 (MOF).
Healthcare Macro Overview
+0 million
population in Saudi Arabia
0 %
under 40 years of age
+0 billion
designated for infrastructure
Allocating
0 billion
to health and social development
0 billion
budget for health and social sectors
Saudi Arabia’s Pharmaceutical Sector is regulated by the Saudi Food And Drug Authority (SFDA)
The government pledged
$0 billion
for healthcare infrastructure (2021 - 2030)
Market Opportunities
The pharmaceutical market is expanding due to localisation, innovation, and government support for biopharmaceuticals, including biosimilars and precision medicine. Private sector investments in advanced manufacturing and partnerships address local and regional demands.
Pharmaceutical Import and Export
Saudi Arabia remains the largest pharmaceutical importer in the GCC, with imports dominating the market, particularly for patented drugs. Localisation efforts are gradually reducing reliance on imports, fostering domestic production.
